Owlstone Medical partners with Thermo Fisher Scientific to advance use of breath samples to detect disease
Owlstone Medical and Thermo Fisher Scientific have entered into a collaboration to advance the use of breath sampling for the early detection of diseases.
Working at Owlstone’s laboratory on Cambridge Science Park, the initial phase will seek to integrate a Thermo Scientific mass spectrometer into the company’s Breath Biopsy platform for the detection of new biomarkers.
Once completed, the technology will become a standard part of Owlstone’s biomarker discovery process, through which metabolomic studies are carried out on breath samples for internal programs, pharmaceutical companies or academic clients with the aim of developing research or clinical tests.
Billy Boyle, co-founder and CEO at Owlstone Medical, which won Life Science Company of the Year at the Cambridge Independent Science and Technology Awards on October 30, said: “The GC Orbitrap platform’s ability to detect a wide range of chemicals during both targeted and untargeted analyses, without losing selectivity or sensitivity, promises to be of substantial benefit to our Breath Biopsy platform.
“With a large and rapidly expanding installed base of GC Orbitrap systems, our partnership with Thermo Fisher Scientific represents an exciting opportunity for cross-promotion of the platform and technique, by which the benefits of Breath Biopsy can be broadly realised.”
Morten Bern, senior director marketing, chromatography and mass spectrometry, of Thermo Fisher Scientific, said: “There is clearly a growing need for non-invasive diagnostic solutions to support the early detection of disease.” said . “The integration of our Orbitrap GC-MS technology with Owlstone Medical’s Breath Biopsy platform provides a unique basis to improve patient outcomes through the discovery of breath biomarkers and their incorporation into clinical practice.”